The Dutch Biomarker Development Center (BDC) is an initiative of the University of Groningen (RUG), the University Medical Center Groningen (UMCG), the Erasmus Medical Center Rotterdam (EMC), the Radboud University Medical Center Nijmegen (RUMC) and Netherlands Organisation for Applied Scientific Research (TNO). The BDC focuses on biomarker verification and validation in a multi-centric setting involving technology-oriented and clinical centers. The major disease areas are Chronic Obstructive Pulmonary Disease (COPD), Diabetes Type II and Alzheimer’s Disease.


New avenues to biomarkers for cervical cancer

A collaboration between the BDC groups at the Erasmus Medical Center in Rotterdam and the University of Groningen led to new insights into molecular changes in squamous cell cervical carcinoma tissue. This work opens new avenues for developing better biomarkers to assess whether early lesions progress to cervical cancer or not. See the article here (Posted on 16 May 2018)

National Xomics platform

The Biomarker Development Center (BDC) is member of the national Xomics (speak Crossomics) platform, which combines proteomics, genomics and metabolomics. Data integration is a major focus of this platform, since new insights into biological and pathophysiological mechanisms and more sensitive and specific biomarker (panels) can only be obtained by understanding the underlying biology at all levels. More details about this initiative can be found here. (Posted on 15 April 2018)

Developing novel methods for protein, peptide and metabolite analysis: an interview with Rainer Bischoff

Rainer Bischoff, Professor of Analytical Biochemistry at the University of Groningen (Groningen, The Netherlands), talks to Sankeetha Nadarajah, Managing Commissioning Editor (Bioanalysis), regarding the development of novel methods for protein, peptide and metabolite analysis. This interview was recorded at the European Biotechnology Forum (EBF) symposium in Barcelona (Spain). You can find the interview here.

Traversing Omics: How Mass Spectrometry Advances Translational Medicine

Professor van Gool's laboratory at Radboudumc specializes in the metabolic side of disease, focusing on proteins, metabolites and enzyme functions, and combines this with insights from Radboudumc's genetic analysis to deliver comprehensive molecular diagnostics. See full report here. (Posted on 21 January 2018)

Biomarker predictive of death after heart failure

The group of Prof. Bischoff (BDC site Groningen) recently contributed to the discovery and validation of a metabolite biomarker that has predictive value for death after heart failure. The collaboration with Prof. van der Meer (University Medical Center Groningen) showed that the enzyme 5-oxoprolinase has a protective effect and that elevated plasma levels of 5-oxoproline are associated with a worse clinical outcome. The results of this study were published in Science Translational Medicine. View Pubmed record here. (Posted on 12 December 2017)

FABIAN Symposium, Groningen

Fabian conference attendees

The 2017 edition of the FABIAN symposium of the Bioanalysis Working Group of the Royal Dutch Chemical Society (KNCV) in close collaboration with the Belgian Bioanalysis Working Group brought together young scientists and experts in bioanalysis during an inspiring day at the ERIBA Institute of the University of Groningen. About 70 participants discussed new possibilities of using high-resolution mass spectrometry in (regulated) bioanalysis.
After an overview given by one of the pioneers of modern mass spectrometry, Prof. Hopfgartner from the University of Geneva (Switzerland), there were presentations related to scientists and practitioners from industry and international research institutes. The afternoon session went into specific examples of therapeutic protein analysis, ultra-high resolution mass spectrometry and proteomics.
The symposium allowed renewing acquaintances and making new contacts. We are looking forward to an equally successful symposium in 2018 to bring the Dutch and Belgian bioanalysis community together again. (Posted on 18 October 2017)

MSACL Lecture, Salzburg

Prof. Rainer Bischoff of the BDC gave a plenary lecture at the MSACL symposium on Mass Spectrometry in the Clinical Laboratory in Salzburg, Austria. The slides can be found here. (Posted on 22 September 2017)

Waters MS Technology Days 2017: Evaluation of biomarkers predictive for Alzheimer's disease

During the Waters MS Technology Days 2017 in Basel (6/27) and Lausanne (6/27) research results were presented from a BDC study carried out in the group of Dr. Theo Luider at the Erasmus MC (Rotterdam) about development and application of an LC-MS assay to evaluate Pregnancy Zone Protein as potential biomarker for the prediction of Alzheimer's disease. Information about the meeting here. (Posted on 24 August 2017)

[News archives]